Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...3435363738394041424344...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Tolerability of first line systemic therapy in elderly patients with advanced hepatocellular carcinoma (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1152;    
    Four patients were excluded from the final analysis due to lack of follow-up (FU) information, 6 patients on atezolizumab/bevacizumab therapy were excluded for less than 3 months of FU at the time of data collection. We studied patients
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    A simple characterization of dynamic changes in circulating (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1147;    
    A prospective cohort of 31 patients treated with atezolizumab+bevacizumab and a control prospective cohort of 15 patients treated with sorafenib or lenvatinib were subjected to repeated blood tests, at baseline and during the course of treatments. Early changes in circulating PD1+CD8+ lymphocytes predict the type of response to atezolizumab+bevacizumab and encourage evaluating this minimally invasive, cheap, easy and repeatable test in a larger cohort of patients to confirm its informativeness in this setting.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1140;    
    The final analysis is expected on June 2023. Figure: Table 1: Severe adverse events Subject PatientID Sorafenib intolerance AE description Start date End date Grade (1-5) NCI CTCAE v5.0 Cabozantinib Relationship Cabozantinib dose (mg) Action taken (Cabozantinib) Death Hypokalemia 2020-09- 09 2020-10- 07 3 Related 60 Cabozantinib interrupted 1 Dermatologic adverse event and fatigue Gastrointestinal bleeding 2020-12- 17 2020-12- 22 3 Related 60 None Yes Ano-rectal Hemorrhage 2020-12- 11 2020-12- 29 3 Related 60 None 2 Rectal ulcer Spontaneous bacterial peritonitis 2021-01- 28 2021-02- 10 3 Not Related 0 None Yes 3 Dermatologic adverse event Intestinal ischemia 2021-01- 16 2021-01- 26 3 (SUSAR)* Related 60 Cabozantinib interrupted No 4 Dermatologic adverse event Fever 2021-04- 03 2021-04- 09 1 Not related 0 None No 5 Not reported Acute cholecystitis 2021-02- 04 2021-02- 18 3 Not related 0 None Yes
  • ||||||||||  sorafenib / Generic mfg.
    Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1117;    
    MYC promotes hepatocarcinogenesis in chronic liver disease and overexpression is associated with poor response. Furthermore, it can also be inferred that poor response to sorafenib could be related immune evasion through overexpression of Treg cells and M2 macrophages in tumor microenvironment.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Downstaging hepatocellular carcinoma with checkpoint inhibitor therapy safely improves access to curative liver transplantation: a case series (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1115;    
    The 3 cases who ultimately received a liver transplant demonstrated no evidence of rejection or recurrence up to 2 years post-transplant. Future studies are needed to further assess the outcomes of a larger sample size as well as evaluate areas of interest, such as optimal timing of CPIT discontinuation prior to transplant and to assess whether novel tumor biomarkers may provide insight into which patients will respond to this intervention.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    A prospective study to assess medication adherence to systemic therapy among patients with hepatocellular carcinoma (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_744;    
    According to the study's findings, several perceived obstacles, including side effects, cost concerns, and a lack of motivation and support, deter patients from taking their medications as prescribed. Our findings highlight the necessity of modifying the perceived barriers and enhancing adherence in a population at risk by implementing prompt interventions.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Apr 11, 2023   
    P1,  N=15, Recruiting, 
    No abstract available Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2023
  • ||||||||||  volrustomig (MEDI5752) / AstraZeneca
    Trial completion date, Trial primary completion date:  A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Apr 10, 2023   
    P1b,  N=70, Recruiting, 
    Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2023 Trial completion date: Mar 2025 --> Oct 2025 | Trial primary completion date: Mar 2025 --> Oct 2025
  • ||||||||||  erfonrilimab (KN046) / Alphamab
    Enrollment change, Trial completion date, Trial suspension, Trial primary completion date, Metastases:  KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent (clinicaltrials.gov) -  Apr 5, 2023   
    P2/3,  N=16, Suspended, 
    These findings support lenvatinib plus pembrolizumab as a potential first-line treatment for Japanese patients with advanced renal cell carcinoma. N=522 --> 16 | Trial completion date: Sep 2024 --> Apr 2023 | Recruiting --> Suspended | Trial primary completion date: Jun 2024 --> Feb 2023
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Retrospective data, Journal, Metastases:  Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma. (Pubmed Central) -  Apr 4, 2023   
    This report documents the frequent occurrence of erythrocytosis during lenvatinib treatment for advanced HCC, likely secondary to EPO secretion by tumor cells through the antiangiogenic activity levatinib. An early and close monitoring of hematologic parameters is, thus, recommended, together with thromboprophylaxis by low-dose aspirin and phlebotomy in case of symptomatic erythrocytosis.
  • ||||||||||  sorafenib / Generic mfg.
    Journal, Real-world evidence, Real-world, Metastases:  Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib. (Pubmed Central) -  Apr 4, 2023   
    An early and close monitoring of hematologic parameters is, thus, recommended, together with thromboprophylaxis by low-dose aspirin and phlebotomy in case of symptomatic erythrocytosis. The GALNT14-rs9679162 "GG" genotype predicted shorter OS in patients with HBsAg-negative aHCC treated with sorafenib, but predicted a favorable response in all patients with aHCC treated with lenvatinib.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Lenvatinib-Associated Erythrocytosis. (Pubmed Central) -  Mar 30, 2023   
    Thus, it is believed to have been the effect of lenvatinib. No abstract available
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC (clinicaltrials.gov) -  Mar 29, 2023   
    P1/2,  N=53, Recruiting, 
    The concept of induction therapy could be applied to other local-regional treatments and drugs combinations in HCC management. Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2024